FDA approves psoriasis pill from J&J that rivals shots Tremfya, SkyriziJohnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots.{}

Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots.https://www.cnbc.com/2026/03/18/icotyde-psoriasis-pill-from-jj-to-rival-tremfya-skyrizi-il-23-shots.html